KSE exchange. Sector: Healthcare. Industry: Biotechnology. Location South Korea, Incheon.

Samsung Biologics Co.,Ltd. [207940.KSSouth Korea

812,000USD5000 (+0.62%)

• At close Thu Oct 06 2022

43,560,473,139 USD
MARKET CAP
.
PE
0.824
BETA (5y)
.
EPS

profit

404%

for 5 years

profit

104%

for 3 years

profit

68%

for 2 years

profit

2%

for 1 year

profit

10%

for this year

About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Samsung Biologics Co.,Ltd.
https://samsungbiologics.com
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.